Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 4Neoplasm Metastasis 3Recurrence 2Pancreatic Neoplasms 2Leukemia, Myeloid, Acute 2Stomach Neoplasms 1Sarcoma, Clear Cell 1Pancreatic Cancer Metastatic 1Myelodysplastic Syndromes 1Lymphoma 1Lung Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1C04.588.274.476.411.307 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × devimistat × Clear all
NCT01832857 2016-12-29

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

Cornerstone Pharmaceuticals

Phase 2 Terminated
7 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡